Loading...
FLNA logo

Filana Therapeutics, Inc.NasdaqCM:FLNA Rapporto sulle azioni

Cap. di mercato US$58.9m
Prezzo delle azioni
US$1.21
US$6.5
81.4% sottovalutato sconto intrinseco
1Y-41.5%
7D-8.3%
1D
Valore del portafoglio
​
Vista

Filana Therapeutics, Inc.

Report azionario NasdaqCM:FLNA

Capitalizzazione di mercato: US$58.9m

Filana Therapeutics (FLNA) Panoramica del titolo

Filana Therapeutics, Inc. è una società di biotecnologie in fase clinica che sviluppa farmaci per le malattie neurodegenerative. Maggiori dettagli

FLNA analisi fondamentale
Punteggio fiocco di neve
Valutazione2/6
Crescita futura0/6
Prestazioni passate0/6
Salute finanziaria6/6
Dividendi0/6

Analisi del rischio

Realizza un fatturato inferiore a 1 milione di dollari ( $0 )

Non ha una capitalizzazione di mercato significativa ( $59M )

Attualmente non redditizio e non si prevede che diventerà redditizio nei prossimi 3 anni


FLNA Community Fair Values

Create Narrative

See what 10 others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Concorrenti di Filana Therapeutics, Inc.

Storia dei prezzi e prestazioni

Riepilogo dei massimi, dei minimi e delle variazioni dei prezzi delle azioni per Filana Therapeutics
Prezzi storici delle azioni
Prezzo attuale dell'azioneUS$1.21
Massimo di 52 settimaneUS$4.98
Minimo di 52 settimaneUS$1.16
Beta-0.78
Variazione di 1 mese1.68%
Variazione a 3 mesi-33.88%
Variazione di 1 anno-41.55%
Variazione a 3 anni-95.20%
Variazione a 5 anni-98.44%
Variazione dall'IPO-99.21%

Notizie e aggiornamenti recenti

Recent updates

Seeking Alpha • Mar 04

Cassava: Low-Cost Pivot Into TSC Epilepsy Is Unlikely To Create Long-Term Value

Summary Cassava Sciences' pivot to TSC via a Yale license deal for simufilam addresses both new indications and reputation issues but faces significant clinical and market challenges. Preclinical studies show simufilam's potential in treating TSC-related seizures, but translating these results to human efficacy remains uncertain. Cassava's strong liquidity with $128.6 million in cash supports early-stage development, yet long-term funding needs may lead to shareholder dilution. Despite strategic moves, Cassava remains a "sell" due to high risks, competition, and the need for significant clinical validation. Read the full article on Seeking Alpha
Seeking Alpha • Nov 07

Cassava Q3 Earnings Review: It Feels Like The End May Be Nigh

Summary Cassava Sciences' stock has declined significantly since its peak, with ongoing skepticism about the efficacy of its Alzheimer's drug, simufilam. Phase 3 trial results for simufilam are anticipated by year-end, which could either validate or disprove its effectiveness. Cassava has faced legal and scientific scrutiny, with key figures resigning and the company settling a $40m SEC penalty. The new CEO remains cautiously optimistic but acknowledges the potential for ambiguous results and the need for further FDA consultations. Read the full article on Seeking Alpha
Seeking Alpha • Jul 24

Cassava Sciences: Turning The Corner Into A Brick Wall

Summary Cassava Sciences' mechanism of action for simufilam has not been independently verified. Simufilam only slows down the progression of solidly mild Alzheimer's disease for one year; it does not stablize mild Alzheimer's disease for two years as the company claims. The FDA is unlikely to approve another drug with limited short-term effectiveness, especially one which while safe is surrounded by so much controversy. Read the full article on Seeking Alpha
Articolo di analisi • Oct 17

Cassava Sciences (NASDAQ:SAVA) Is In A Good Position To Deliver On Growth Plans

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Articolo di analisi • Jul 04

We're Hopeful That Cassava Sciences (NASDAQ:SAVA) Will Use Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Articolo di analisi • Mar 05

We're Not Very Worried About Cassava Sciences' (NASDAQ:SAVA) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Articolo di analisi • Nov 19

Cassava Sciences (NASDAQ:SAVA) Is In A Good Position To Deliver On Growth Plans

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Oct 13

Cassava Sciences begins extension study of Alzheimer's drug simufilam

Cassava Sciences (NASDAQ:SAVA) has begun an open-label extension study of its Alzheimer's disease candidate simufilam that will last a year. The trial is expected to enroll ~1.6K participants. Enrollment is set to begin in November. The study is for participants that have completed one of the company's two phase 3 trials. They will be given 100 mg simufilam twice daily. Seeking Alpha contributor Biotech Beast views Cassava Sciences (SAVA) as a strong sell as there is still a great deal of uncertainty hanging over the stock.
Seeking Alpha • Sep 29

Cassava Sciences Stock: Huge Returns Or Catastrophic Losses

Summary This is a highly speculative bet. There has been a constant litany of accusations of wrongdoing on the science. There have been several recent positive developments. The data readouts will be massive catalysts. This is such a binary investment you will either do very well, or be left holding the bag. It has been quite some time since we checked on the very volatile and controversial Cassava Sciences (SAVA). At last check, we felt this was going to remain one of the most controversial and volatile stocks as we had into 2022. We are ultimately bullish on the science, but the stock action has been akin to gambling. The stock got pushed down hard this year as a number of questions regarding the research and business practices were raised. The thing is that this stock can make you some really fast gains on both the long and short side of the trade. However, we see the potential for multiple orders of gains should the science hold up here. In other words, it makes a great swing trading stock, but for the medium/long term, you are essentially buying a possible play that could see 5-10X gains, or be worthless, all depending on the science and how it plays out. The science called into question The science has been getting called into question for over a year. That has impacted the crazy volatility even further, and is why it is one of those stocks that lead many to consider Wall Street a casino. The ultimate question is can their drug, simufilam, designed to treat Alzheimer's disease work? We are hoping for humanity's sake that one of the companies working on this type of treatment finds success. Alzheimer's is a horrible affliction and has impacted many of our lives in some capacity or another. So there is a lot of hope with these research candidates under study, such as simufilam, for those suffering from Alzheimer's as well as their loved ones. There just are not effective treatments on the market. That said, the initial data readouts have been positive, but have been met with extreme criticism. You may recall that the interim analysis demonstrated a 1.6 point improvement in the ADAS-Cog11 system in Alzheimer's patient's cognition level rating. So what? Well as it turns out, that is a 10% average improvement. The readout also showed that there was a near 30% improvement in behaviors such as agitation and fear. Those were good results. The constant mantra has been that the company has falsified and manipulated data to make the drug look better. This has cast a cloud on the company and shares have suffered for months. But things are looking up. Some positive developments There has been some insider buying as well. A director, Richard Barry, bought 36.16K shares of common stock at $23.79 on Aug. 23 for $860K. This was an increase in the position of nearly 20% and Barry now has ownership of 186,159 shares. The stock has almost doubled since then. Volumes are up the last month, but the most beneficial news was the recent clearing by one medical journal of the company doing anything wrong in terms of data manipulation. The company has been accused of research misconduct by several entities. There continue to be bears putting their faith in accusations of some possible misdealings related to data collection and reporting. Last year we saw scientific victory, in The Journal of Neuroscience. In that review by the Journal of Neuroscience, an investigation and critical review showed no evidence of data manipulation in one of the technical papers that was an early key to effectiveness of simufilam. Back in 2012 when the drug was first being looked at for possible effectiveness, the accusations from the group claimed the data was manipulated and false. The company responded saying these allegations were false. Essentially they claimed the western blots, which measure proteins and changes, were falsified. Recently the Neuroscience journal reviewed data, and there is once again "no evidence to support claims of data manipulation in a 2005 paper" authored by the company and its scientific collaborators. This summer a scientist called into question foundational research on amyloid plaque theory, as basis for simufilam's target work. Then just a few weeks ago, the journal had cleared the company of scientific misconduct. Then, with little coverage surprisingly, the SEC which was investigating the company also concluded that they recommend closing their investigation. This work was covered in great detail by fellow contributor Jacob Braun. With the huge short interest in the stock, trading has been wild and the stock has rallied. Needless to say, it has been a journey. But the company is not out of the woods entirely. Cassava is still awaiting the results of an investigation from The City University of New York on one of its own researchers who published positive results on simufilam that has come under some of the same data related scrutiny. There is also controversy after the company was accused of being investigated by the Justice Department, something the company denied vehemently. Looking ahead As we look ahead, the company has enough cash to fund operations for at least two more years. It has nearly $200 million in cash and absolutely no debt. The company spends anywhere from $15-$25 million a quarter (more when trials underway, and being set up), so that is at least two years of funding. We believe that with pending data readouts, the investment thesis will have played out by then, as the drug will likely be considered successful or a failure. It may even be approved.
Seeking Alpha • Sep 21

Cassava Sciences: Trying To Manage Expectations

Summary The second group of patients on simufilam on average experienced a .2 point decline in ADAS-Cog scores after one year. These results are similar to acetylcholinesterase inhibitors for mild Alzheimer's disease. Critics claim that some individuals in the first group who experienced a mean improvement of 3.2 did not have Alzheimer's, whereas supporters claim this is true for the second group. Accurate MMSE numbers for both groups would add more clarity to the situation. The apparent mechanisms of action for simufilam suggest that further decline from baseline is likely. An explanation is needed as to why the first group of fifty trial participants on Cassava Sciences' (SAVA) simufilam experienced a 3.2 improvement in ADAS-Cog scores while the second group experienced a .2 point decline. Critics have asserted that at least some of those in the first group did not have Alzheimer's disease. Cassava Sciences advocates apparently taking their cue from the company now have tried to flip the script by arguing that some in the second group did not have Alzheimer's disease but instead had some other form of dementia or mixed dementia, such as Alzheimer's disease and vascular dementia. That is why they did not perform as well. It is impossible to resolve this controversy with the data at hand, but there are clues to a possible answer. According to Cassava Sciences, the first group had a mean ADAS-cog score of 15.5 and a mean MMSE score of 22.1, but a mean ADAS-cog score of 15.5 corresponds to a mean MMSE score of 25.5 (table one). An MMSE score of between 21 and 24 is usually indicative of mild Alzheimer's disease. Some of those with higher MMSE scores in the first group may have been allowed into the trial based on being amyloid positive. But being amyloid positive is not the same thing as having Alzheimer's disease. Individuals with strong antioxidant levels in their brain can have significant amounts of amyloid and not have Alzheimer's disease (study). It is likely, then, that some people in the first group had mild cognitive impairment, very early Alzheimer's disease, or were cognitively normal. The results from the second group of 50 patients are even more difficult to interpret because there is no public record of their baseline scores and characteristics: MMSE scores, ADAS-cog scores, age, gender, ethnicity, APOE4 status, etc. Nothing. The contention made by some of the company's backers is that some individuals in this group did not go under intensive testing to determine if they had Alzheimer's disease. If that is the case, then some participants were admitted into the trial based solely on their MMSE scores. Just like amyloid, MMSE scores alone cannot be used to provide a definitive diagnosis of Alzheimer's disease. So it is possible that a few of these individuals had either some other form of dementia or mixed dementia. But even if this is the case, treatments that lessen oxidative stress in Alzheimer's disease are likely to have at least some benefits in terms of cognition for those with other forms of dementia (possibility). Knowing the actual MMSE scores of the trial participants in both groups would not completely resolve this debate, but it would go a long way in that direction. If there is a significant gap in terms of baseline MMSE scores between the two groups, this would strongly indicate (but not prove) that more people in the second group had mild Alzheimer's disease than in the first group. If the .2 point decline is reflective of the effects of simufilam for mild Alzheimer's disease, this would put it right in line with acetylcholinesterase inhibitors for mild Alzheimer's disease (chart). And this may be no accident. Acetylcholinesterase inhibitors such as Aricept inhibit oxidative stress as sigma-1 agonists and are peroxynitrite decomposition catalysts (a nitro-oxidant that probably plays a key role in Alzheimer's disease). Simufilam potentially at least can do the same (previous article). About 20 percent of the population does not have a functioning sigma-1 receptor, so they do not benefit from this form of treatment. Sigma-1 receptor activity declines with the progression of Alzheimer's disease, so this type of treatment does not work nearly as well for moderate Alzheimer's disease as it does for mild Alzheimer's disease. This may explain why some participants responded better to simufilam than others. Not only the results but probably the mechanism of action of simufilam is in need of adjustment. Cassava Sciences has always presented itself outside the realm of various other anti-amyloid treatments, but it too is an amyloid-centric approach. The company's stated mechanism of action is that by restoring filamin A to its normal configuration, it reduces amyloid toxicity by "disabling its signalling" via nicotinic acetylcholine and toll-like receptors (publication). Yet, in trials where nearly all amyloid was removed, Alzheimer's disease continues to progress. It does not take a very small amount of amyloid to contribute to Alzheimer's disease, it requires a lot (such as the case with APOE4 carriers). In non-APOE4 carriers who have less amyloid, anti-amyloid drugs don't work at all (latest example from Eli Lilly). It is possible that simufilam produces beneficial results even in the absence of amyloid. For instance, simufilam may be a zinc and copper chelator, which may be of some significance in that zinc and copper contribute to the misfolding of proteins as well as to their toxicity. If this is the case, then it is the presence of copper and zinc and not any particular misfolded protein that can at least early on contribute to the progression of Alzheimer's disease. Eventually, though, copper and zinc are entombed in amyloid plaques, so their role in Alzheimer's disease declines. It is possible, though, that a small part of simufilam's early benefit is as a copper and zinc chelator. The role of misfolded proteins by themselves in Alzheimer's disease is somewhat uncertain. Misfolded amyloid by itself probably does no damage to the brain. Misfolded tau proteins can inhibit neurotransmissions. It is unclear at this point if misfolded filamin A proteins do any damage to the brain or not.
Seeking Alpha • Sep 09

Cassava Sciences reaches over five-month high on rising volumes

After a sharp selloff early this year, clinical-stage biotech Cassava Sciences (NASDAQ:SAVA) appears to be turning the tide, with its shares rising for the fourth straight session Friday on above-average volume to reach the highest level since April. Nearly 2.9M SAVA shares have changed hands so far, compared to the 65-day average of ~2.4M. The upsurge comes as SAVA, a developer of an Alzheimer’s therapy, is set to participate in an investor conference organized by H.C. Wainwright next week. SAVA stock crashed in late July after Reuters reported that the U.S. Justice Department had initiated a criminal probe over its experimental Alzheimer’s therapy, a claim company denied. Despite a ~31% selloff in 2022, SAVA shares have recovered since then, adding ~78% to strongly outperform the ~5% gain of the SPDR S&P Biotech ETF (XBI). The rally coincided with two recent insider purchases, including those from Directors Sanford Robertson and Barry Richard. Robertson, the principal of technology buyout fund Francisco Partners, bought 100K SAVA shares in August for over $2M to raise his stake by ~11%.
Seeking Alpha • Sep 03

Cassava Sciences Looks As Good Of A Purchase As Ever

Summary Multiple insiders have purchased shares on the open market in the last month. The company has now released positive 100 patient 12-month data. Another journal cleared the company of any wrongdoing. The SEC has officially ended any inquiries into the company. Introduction I give a strong buy rating to Cassava Sciences (SAVA). Throughout the drops, I have continued to add shares and DCA. In the past, I called Cassava Sciences the best risk to reward in the stock market, and when the price becomes even more attractive over noise, it makes it an even better risk to reward. Big pharma spent billions of dollars searching for drugs to help patients with Alzheimer's Disease ((AD)). Yet, a small former pain company out of Austin, Texas – a place not known as a biotech mecca – has released data that blows everybody else's products out of the water. Unlike its competitors' expensive, impractical IV solutions full of safety issues, Cassava Sciences' solution is a small pill without known safety concerns. From the graveyard of AD therapy has come life called Simufilam. Because of this unlikeliness, the company has been shorted down to pennies of its all-time highs achieved last summer. While shorting a highly hyped stock is usually a brilliant bet, based on looking at all claims for and against the company, I believe that Cassava Sciences has seemingly done the impossible. You can read my bullish public coverage going back well over a year on Seeking Alpha and my reasons for my strengthening belief below. Four Bullish Events Since We Last Spoke As stated by Peter Lynch, "Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise." And buy the Cassava Sciences insiders have done. Since the last quarterly report, four insiders have purchased over $3 million in shares on the open market, including longtime Salesforce (CRM) board member and supporter of Neuroscience Sanford Robertson, increasing his share position by ~10% to push him past 1 million shares. In addition to the above buying, no insider has sold shares for years. Insiders have privileged information, and their moves speak volumes. These insiders are yelling very loudly as they try to get their hands on as many shares as possible. The last insider buy on the open market was September 24th, 2020, shortly before the stock rose in the summer of 2021 to over $100 and became the top performing stock of the year. Even more importantly, this was three months before the company announced its groundbreaking six-month OLE results. The company insiders likely had a closed buying period shortly after that purchase and at least through the data announcements of 2021. September 2020 was most likely the last time insiders had the chance to buy on the open market, considering we have not seen any buys between these two open market buys. One thing that undoubtedly strengthened the insiders' belief was when on August 3rd the company announced 12-month data for 100 patients from its phase 3 trials. While the second 50 cohort was admittedly not as good as the first 50, the second 50 was still very good. Highlights from the data are that 63% of patients improved cognition, a remarkable achievement considering that AD is a disease of continual decline. Additionally, another 21% of patients slowed less than five cognitive points, meaning that the drug was able to slow down the effects of AD. Overall, 84% of patients saw a positive impact from the drug. If the company is able to achieve a result anywhere close to this while the drug's safety profile remains impeccable, then I would be shocked if they were unable to secure approval. The 100 patient data further de-risks the stock by decreasing the chances of a phase 3 failure. In the middle of the frenzy of insider buyers, a surprise occurred when yet another scientific journal found no data manipulation in Cassava Science's scientific publications on Simufilam. The Journal of Prevention of Alzheimer's Disease ((JPAD)) is a positive step in the right direction while we wait for critical regulatory clearance from the City University of New York ((CUNY)). Many retail investors question the importance of CUNY, but that is because its importance is not for retail investors. Instead, its importance is for institutional investors. I speculate that this is the hold-up for many institutions purchasing the stock, resulting in very low institutional ownership. Institutions have to answer to their clients, and no matter how good the data for Cassava Sciences look, if an institution invested before a CUNY clearance and CUNY ruled against Cassava Sciences, then the institution would have some severe repercussions to face. While we are still waiting on CUNY, we have positive news that the SEC has concluded all its inquiries into the company. From SEC investigation expert John P Gavin from Disclosure Insight's work, we can tell that the SEC performed an extensive inquiry into Cassava Sciences, totaling 48 boxes of documents that did not end in any formal investigation. CEO Remi Barbier said the company gave "nearly 100,000 pages of documents to an alphabet soup of outside investigative agencies … [they have] yielded an important finding to date: there is no evidence of research misconduct." Commercially bought paper comes in 5000 pages for a box, but loose leaf paper fits much looser in a box. From my research, only about 2500 pieces of loose leaf paper can fit in a box, so the number of documents from this quote aligns with the 48-box comment from the SEC. Regardless of the amount, it is in the rearview mirror for the company. Events on the Horizon Before the end of the year, Cassava Sciences should release 12-month data for 200 patients from its OLE trial, which will further boost the odds of success in phase three trials if the data continues to be positive. Additionally, the company will release 12-month biomarker data for 25 patients, which will provide another validation for Cassava Sciences' data results. Something to remember is that Aduhelm from Biogen (BIIB) was approved based on biomarker data, not cognitive data. Looking ahead, mid-2023 should yield the results of the company's cognition maintenance study showing data from patients on the drug for 18 months and having the first placebo-controlled data. Finally, the company will have completed phase three trials in early to mid-2024, whose results will determine whether or not Simufilam gets approved. The coming two years will be exhilarating for Cassava Sciences' investors. Financials
Seeking Alpha • Aug 26

Cassava Sciences stock jumps 10% after director buys $860K shares

In a regulatory filing, Cassava Sciences (NASDAQ:SAVA) disclosed that its director Richard Barry bought 36.16K shares of common stock at $23.79 on Aug.23 for a total outlay of $860K. The move leaves Richard Barry with ownership of 186,159 shares. A quick look at the company's ownership structure: Shares of Cassava Sciences are up 10.37% afterhours at $30.11.

Rendimenti per gli azionisti

FLNAUS PharmaceuticalsUS Mercato
7D-8.3%-1.7%2.0%
1Y-41.5%36.7%23.3%

Ritorno vs Industria: FLNA ha avuto una performance inferiore rispetto al US Pharmaceuticals che ha registrato un rendimento 36.7 % nell'ultimo anno.

Rendimento vs Mercato: FLNA ha avuto una performance inferiore al mercato US che ha registrato un rendimento 23.3 % nell'ultimo anno.

Volatilità dei prezzi

Is FLNA's price volatile compared to industry and market?
FLNA volatility
FLNA Average Weekly Movement8.6%
Pharmaceuticals Industry Average Movement10.3%
Market Average Movement7.2%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.1%

Prezzo delle azioni stabile: FLNA non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi rispetto al mercato US.

Volatilità nel tempo: La volatilità settimanale ( 9% ) di FLNA è rimasta stabile nell'ultimo anno.

Informazioni sull'azienda

FondatoI dipendentiAMMINISTRATORE DELEGATOSito web
199819Rick Barrywww.filanatx.com

Filana Therapeutics, Inc. è una società di biotecnologie in fase clinica che sviluppa farmaci per le malattie neurodegenerative. Il suo principale candidato terapeutico è il simufilam, un farmaco a piccola molecola, che è in fase di sperimentazione clinica di Fase 3 per il trattamento della malattia di Alzheimer; e il candidato diagnostico in fase di sperimentazione è SavaDx, un programma in fase iniziale incentrato sulla rilevazione della presenza della malattia di Alzheimer da un piccolo campione di sangue. L'azienda era precedentemente nota come Cassava Sciences, Inc. e ha cambiato nome in Filana Therapeutics, Inc. nel marzo 2026.

Filana Therapeutics, Inc. Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Filana Therapeutics con la sua capitalizzazione di mercato?
FLNA statistiche fondamentali
Capitalizzazione di mercatoUS$58.94m
Utili (TTM)-US$77.90m
Ricavi(TTM)n/a
0.0x
Rapporto P/S
-0.8x
Rapporto P/E

FLNA è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Utili e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
FLNA Conto economico (TTM)
RicaviUS$0
Costo del fatturatoUS$17.47m
Profitto lordo-US$17.47m
Altre speseUS$60.43m
Utili-US$77.90m

Ultimi utili riportati

Mar 31, 2026

Prossima data di guadagno

n/a

Utile per azione (EPS)-1.61
Margine lordo0.00%
Margine di profitto netto0.00%
Rapporto debito/patrimonio netto0%

Come si è comportato FLNA nel lungo periodo?

Vedi performance storica e confronto

Analisi aziendale e situazione dei dati finanziari

DatiUltimo aggiornamento (ora UTC)
Analisi dell'azienda2026/06/17 04:39
Prezzo dell'azione a fine giornata2026/06/17 00:00
Utili2026/03/31
Utili annuali2025/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

PacchettoDatiTempisticaEsempio Fonte USA *
Dati finanziari della società10 anni
  • Conto economico
  • Rendiconto finanziario
  • Bilancio
Stime di consenso degli analisti+3 anni
  • Previsioni finanziarie
  • Obiettivi di prezzo degli analisti
Prezzi di mercato30 anni
  • Prezzi delle azioni
  • Dividendi, scissioni e azioni
Proprietà10 anni
  • Top azionisti
  • Insider trading
Gestione10 anni
  • Team di leadership
  • Consiglio di amministrazione
Sviluppi principali10 anni
  • Annunci aziendali

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Filana Therapeutics, Inc. è coperta da 5 analisti. 2 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

AnalistaIstituzione
Gregory FraserBofA Global Research
Mayank MamtaniB. Riley Securities, Inc.
Elemer PirosLucid Capital Markets